USA Today: FDA to Consider Fate of Diabetes Drug Avandia
The internal battle at the FDA over dangerous diabetes medication Avandia will come to a head tomorrow at a long-awaited advisory board meeting. GAP client Dr. David Graham recently authored a study, published in the Journal of the American Medical Association, detailing the increased risk of heart attack or stroke for patients taking the drug.
The article above details an internal memo from an FDA scientist stating that one of the drug’s clinical trials "‘was inadequately designed and conducted to provide any reassurance’ that the controversial diabetes drug does not increase cardiovascular risk.” GAP published a report last year on the urgent need for FDA clinical trial reform.
Similar Article: Wall Street Journal
PC Magazine: Wikileaks not Quite so Abandoned after all
There are blog rumors that the controversial site Wikileaks.org is to be abandoned by its managers and creators. But this article quotes a Wikileaks spokesperson as denying that assertion. Furthermore, it seems that Wikileaks may simply be switching servers. Reasons for this are unclear.
Washington Post: Digging Deep after the Oil Spill
The Deep Horizon oil spew disaster has prompted at least nine formal investigations into the accident, events leading up to it, and actions taken since. This article details all nine, and each one’s focus.
Dylan Blaylock is Communications Director for the Government Accountability Project, the nation's leading whistleblower advocacy organization.
